Neurocrine Biosciences Inc (NBIX)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$145.20

Buy

$165.00

arrow-down$-1.95 (-1.26%)

Prices updated at 12 Dec 2025, 21:22 EST

Prices minimum 15 mins delay

Prices in USD

Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Income statement

Year chevron-l-regular chevron-r-regular	2023	2024
	1,887m	2,355m
	1,847m	2,321m
	395m	583m
	20.92	24.75
	250m	341m
	416m	640m
Sales, General and administrative	888m	1,007m
Interest expenses	-	127m
Provision for income taxes	82m	145m
Operating expenses	1,453m	1,738m
Income before taxes	332m	486m
Net income available to common shareholders	250m	341m
	2.56	3.4
Net interest income	53m	-36m
Advertising and promotion	-	-
Net investment income, net	-	-
Realised capital gains (losses), net	-	-
Total benefits, claims and expenses	-	-
Earnings per share (diluted)	2.47	3.29
Free cash flow per share	3.8231	4.2501
Book value/share	20.2847	27.3531
Debt equity ratio	0.115726	0.175735

Balance sheet

Year chevron-l-regular chevron-r-regular	2023	2024
Current assets	1,607m	1,725m
Current liabilities	655m	508m
Total capital	2,232m	2,590m
Total debt	428m	455m
Total equity	2,232m	2,590m
Total non current liabilities	-	-
Loans	-	-
Total assets	3,251m	3,719m
Total liabilities	-	-
Cash and cash equivalents	251m	233m
Common stock	99m	99m

Cash flow

Year chevron-l-regular chevron-r-regular	2023	2024
Cash at beginning of period	271m	259m
Cash dividends paid	-	-
	362m	557m
Investments (gains) losses	-467m	-127m
	259m	241m
Net income	-	-
	390m	595m
	-28m	-38m

The figures shown in the tables are quoted in the currency of the stock selected.

Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.